Archives ofDisease in Childhood 1995; 72: 544 from 0-20 mmolfl at baseline to 0 55 mmol/l at three months and then dropped to 0 4 mmol/l at seven months. The changes in markers of bone turnover are as shown in the table with a more than twofold rise in serum osteocalcin and the carboxyterminal propeptide of type 1 collagen (PICP) as markers of bone formation and a 1-5 fold rise in the level of the carboxyterminal cross linked telopeptide of type 1 collagen (ICTP) and urinary hydroxyproline/creatinine ratio (OHP/Cr) as markers of bone resorption. These reflect the general increase in bone turnover induced by growth hormone treatment. 
